steadi improv continu upsid still
recent underli perform encourag expect steadi
improv continu pickup acquisit activ also bode well
futur posit analysi suggest firepow
could drive valu accret share price still see materi upsid
underpin steadi execut margin opportun balanc sheet
scope ep rais pt gbp
msd organ growth within grasp view focu sinc onboard
current ceo drive commerci effect delay
manag structur franchise-focus commerci model view
recent result organ growth indic oper
progress made expect organ growth improv toward msd
underpin product launch strength em better execut across
board particular believ aet awb posit return posit
growth support fy organ growth top end
see scope margin improv apex programm
expect save remain track deliv cost save
support margin expans period
assum margin expans vs consensu
continu deliveri apex off-set reinvest see
scope improv cost effici given sn/ opex sale
higher manag commentari suggest sn/
identifi opportun could expand overal cost save amount
capit deploy could drive signific growth acceler valu sn/
step pace recent spent complet five bolt-
deal acquisit provid innov product key
acceler group growth out-performance view given sn/ robust
balanc sheet current lever cash flow gener estim
compani would firepow bolt-on deal next three
year assum deal in-lin sn/ past transact term see exhibit
analysi suggest opportun could drive valu accret
share price
recent re-rat yet price cost effici upsid ytd share
return driven earn upgrad multipl re-rat
still see materi upsid underpin steadi execut margin
opportun balanc sheet scope sn/ current trade price-to-earnings
ep compound-annual-growth-rate vs eu med-tech rais ep
pt gbp includ upsid potenti
pleas see analyst certif import disclosur inform inform regard statu non-u analyst
page report
steadi improv execut provid credibl
path toward organ growth margin
continu out-performance sport knee
wound devic aet awb return growth
current address market
shift higher-growth segment
signific margin upsid oper leverag
effici measur
market condit turn less favour result
margin declin loss oper leverag
credibl path toward organ growth
effici mitig risk recurr
materi upsid bolt-on acquisit
increas exposur higher growth area
close profit gap vs peer
strong balanc sheet cash flow gener
provid scope capit deploy
pleas see import disclosur inform page report
 potenti remain underappreci view
sn/ step pace recent spent complet
five bolt-on deal acquisit provid innov product key
acceler group growth view osiri contribut sn/
group sale organ growth apart execut issu believ
sn/ rel sluggish activ vs peer past result
widen gap two compani organ growth perform
therefor see opportun sn/ improv growth profil bolt-
acquisit shift current portfolio mix jefe lsd growth
exhibit key factor widen gap
sn/ histor organ growth perform
exhibit histor valuat multipl sn/ eu
pleas see import disclosur inform page report
organ growth price-to-earnings xsn-gb-useu medtechclos dateacquisit targettransact valu jul srl -- -optic track technolog apr healthcar inc -- -patient monitor system pressur injuri apr inc jun ag /orthopaed busi -- -digit workflow jan orthopaed inc repair dec medic inc rotat cuff jan belt inc surgeri jul group /trauma orthopaed busi -- -russian distrbut jun biomet/unicompartment knee -- -sale part colombia sa -- -distributor may corp repair portfolio exhibit past complet deal
given sn/ robust balanc sheet current lever cash flow gener
estim compani would firepow bolt-on deal
next three year assum deal in-lin sn/ past transact profil
analysi suggest opportun could drive valu accret
analysi potenti valu bolt-on acquisit make follow
compani make singl larg invest dec
 firepow assum compani leverag
net debt/ebitda utilis free cash flow
compani acquir sale multipl
initi ebitda margin improv group level year
sale growth year moder year
 acquir asset sale
effect tax rate in-lin sn/ group rate
capex/d ratio
wacc
terminal-growth rate
pleas see import disclosur inform page report
close dateacquisit targettransact valu ltd therapi sever torn rotat feb inc -- -cryoablat technolog chronic oct medic technolog inc polym cross-link oct inc visual surgic group hold inc may servic inc -- -reprocess patient care single-us apr sa compress fractur vcf dec gmbh -- -surgic navig feb medic inc invas treatment ent dec stake vexim sa compress fractur vcf dec stake vexim sa compress fractur vcf sep inc oct medic solut inc -- -patient safeti dec surgic llc -- -extrem sep sport medicin llc -- -minim invas menisc repair apr implant world-wide ltd orthopaed apr augment busi -- -vertebr compress fractur apr inc autom extern defibril apr usa inc /neuro portfolio busi -- -neurosurg apr product llc safeti sep metal -- -hospit jan hospit bed inc -- -hospit bv /ent surgeri busi -- -ent oct bone innov inc innov inc -- -implant lower lumbar medic inc -- -sport medicin apr gmbh co kg infrastructur equip exhibit sn/ potenti analysi
pleas see import disclosur inform page report
model impactusdmd assumptionsmax leveragesal growth net debt debt net corp growth free cash margin capit contract revenu ebitda firmusdmyear ebitda margin pre acquir margin improv tax capital-expenditure capit work work pv valu valu valu equiti research
provid sensit analysi increment valu sn/
assum differ transact multipl sale revenu growth ebitda margin
exhibit sensit sale multipl revenu growth
exhibit sensit sale multipl annual ebitda
outlin impact potenti acquisit given assumpt
acquisit earn accret year return invest capit
exceed group cost capit year profil line sn/ past
transact view
exhibit impact potenti acquisit
pleas see import disclosur inform page report
acquir sale annual xebitda margin improv xp effect tax minor interest -- -- -combin net equiti research
pleas see import disclosur inform page report
sale medicin wound exhibit incom statement
pleas see import disclosur inform page report
